Nightingale Health
Disease prediction from blood
Helsinki, Finland
Nightingale Health leverages Nuclear Magnetic Resonance (NMR) spectroscopy to analyze approximately 250 biomarkers from blood samples. Their technology is used to identify early risk signs for common diseases like heart failure, dementia, and diabetes, offering chronic disease risk detection capabilities. The company focuses on B2B and B2G markets, with strategic partnerships for global scaling of its digital health solutions.
How We Help
Core Technology
Nuclear Magnetic Resonance (NMR) spectroscopy to measure approximately 250 active biomarkers from a single blood sample
Clinical Focus
chronic disease risk detection
Company Info
- Business Model
- Licensing
- Founded
- 2013
- Total Funding
- 9,504,000
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Nature Communications 2024: Metabolomic scores predict disease onset better than polygenic scores in 700,217 participants. Landmark study shows 44% improvement in cardiovascular event prevention. 39 CE-marked biomarkers. Validated in UK Biobank (118,461 participants) and international cohorts.
MedStartr Index Score
?What do you think of Nightingale Health?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.